According to reports, IL-17 dramatically improves plasma cell survival through p38-mediated stabilization of the Bcl-xL gene221 and sustains plasma cells in SLE.222 It is possible that blockade of these pathways, either separately or in combination, may be effective for the treatment of SLE. The gene discussed is IL17A; the disease is systemic lupus erythematosus.